Post by Gubra

Name: We saw a strong start to 2026 at Gubra. In Q1, we continued to advance our biotech portfolio with
Uploaded: 2026-05-06T06:43:32.333Z
Channel: Gubra
Description: We saw a strong start to 2026 at Gubra. In Q1, we continued to advance our biotech portfolio with solid progress across key clinical programs, including obesity assets moving towards Phase 2 – ABBV-

26,251 followers

We saw a strong start to 2026 at Gubra. In Q1, we continued to advance our biotech portfolio with solid progress across key clinical programs, including obesity assets moving towards Phase 2 – ABBV-295 (Amylin) and BI 3034701 (first-in-class triple agonist – and an important step towards first-in-human studies for GUB-UCN2. We also launched Gubra Ventures, opening a new chapter in accelerating innovation and future growth. At the same time, our CRO business showed resilience in a challenging market, delivering strong quarter-on-quarter growth and expanding into new therapeutic areas. A quarter of progress, momentum and ambition. Read full Q1 trading statement here: https://lnkd.in/ditGp8AP #Q1TradingStatement #Q1Results #Biotech #CRO #DrugDevelopment #Ventures

Video Content